Singapore markets close in 27 minutes

Verve Therapeutics, Inc. (VERV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
43.39-0.54 (-1.23%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close43.93
Open43.72
Bid0.00 x 900
Ask0.00 x 800
Day's range42.65 - 44.51
52-week range29.50 - 78.00
Volume176,966
Avg. volume385,787
Market cap2.108B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-25.50
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est72.33
  • Motley Fool

    2 Gene-Editing Stocks to Have on Your Radar Right Now

    They only have preclinical candidates for now. But these biotechs could have game-changing gene-editing therapies.

  • Motley Fool

    Ignoring Monday's 2 Big Nasdaq Winners Could Cost You Serious Money

    The stock market got off to a mixed start on Monday, but that wasn't evident to investors in the Nasdaq Composite (NASDAQINDEX: ^IXIC). As it often has before, the Nasdaq pushed higher even as other major market benchmarks fell, with gains of about two-thirds of a percent as of 11:30 a.m. EDT. Plenty of the Nasdaq's biggest stocks were among the gainers to start the new week.

  • Business Wire

    Verve Therapeutics Announces Pricing of Initial Public Offering

    CAMBRIDGE, Mass., Jun 17, 2021--Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the pricing of its initial public offering of 14,035,789 shares of its common stock at a price to the public of $19.00 per share. The gross proceeds to Verve from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $266.7 million. All of the s